Monoclonal antibody anifrolumab shows success against lupus

The addition of anifrolumab to usual lupus treatment has been shown to improve disease activity and reduce glucocorticoid use in adult patients with moderate to severely active SLE.   The phase 3 TULIP-2 trial assessed the effect of  the monoclonal antibody- which inhibits signalling through the type I interferon receptor – in 362 patients from 16 ...

Already a member?

Login to keep reading.

© 2021 the limbic